



17 March 2020

Sydney, Australia

Veyonda[®] Awarded First Allowed Patent Application

Highlights

- Australian Patent Office awards allowance on Veyonda[®] patent application
 - Important step in securing IP protection over commercial opportunity
 - Patent term through until July 2036
-

Sydney, 17 March 2020: Noxopharm (NOX:ASX) announces that Australian patent application No. 2016401508 has been allowed by the Australian Patent Office.

The patent claims are directed to a suppository formulation including idronoxil and the allowed claims provide broad coverage for Veyonda[®] as a therapeutic.

Graham Kelly, Noxopharm CEO, said, “This news is an important step forward for the Company and will go a long way to underpinning our proprietary ownership of Veyonda[®] and what we see as its considerable potential commercial value given the strength of the emerging clinical data.”

“To date we have lodged 5 families of patents, with a 6th family currently being prepared, all part of an aggressive strategy of building as many patent fences as possible around Veyonda[®] in major drug territories. The patent allowance announced today is for the very first family and is the most fundamental patent application we have lodged. Collectively, all 6 families are designed to build a substantial IP portfolio around the clinical use of Veyonda[®]. This portfolio will play an important part of anticipated future partnership negotiations.”

This patent application is also being pursued in the United States, Europe, Japan, China, Canada, India, Israel, South Korea, New Zealand, Russia, Singapore and Hong Kong.

About Veyonda[®]

Veyonda[®] is a suppository dosage form of idronoxil, a first-in-class inhibitor of sphingosine-1-phosphate (S1P). S1P is a key secondary messenger in cells, with dual roles of activating major pro-survival signalling pathways and regulating immune cell trafficking in tissues. Many solid cancers over-express S1P, supporting



unregulated tumour growth and suppressing immune cell populations in tumours. By inhibiting the over-expression of SIP-driven pro-survival pathways, idronoxil is designed to sensitise cancer cells to the anti-cancer effects of drugs such as doxorubicin, as well as to radiation. By inhibiting the over-expression of SIP-driven exclusion of immune cells from tissues, idronoxil is designed to restore normal trafficking of immune cells.

About Noxopharm

Noxopharm is a clinical-stage Australian oncology drug development company with offices in Sydney and New York. The Company has a primary focus on the development of Veyonda® and is the major shareholder in the non-oncology drug development company, Nyrada Inc. (ASX:NYR).

www.noxopharm.com

Investor & Corporate enquiries:

Prue Kelly
M: 0459 022 445
E: info@noxopharm.com

Company Secretary:

David Franks
T: +61 2 8072 1400
E: David.Franks@automicgroup.com.au

Media enquiries:

Catherine Strong
Citadel-MAGNUS
T: 02 8234 0111
E: cstrong@citadelmagnus.com

Graham Kelly, CEO and Chairman of Noxopharm, has approved the release of this document to the market.

Forward Looking Statements

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.